IN THE UNITED STATES PATENT AND TRADEMARK OFFICE Group Art Unit 1623

In re Patent Application of

Electronically filed by Sally Sorensen

Paul B. Savage

Application No. 10/550,165

Confirmation No.: 5240

Filed: July 21, 2006

Examiner: Ganapathy Krishnan

"6"-AMINO-6"-DEOXYGALACTOSYLCERAMIDES"

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT **PURSUANT TO 37 C.F.R. § 1.97(c)**

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The Examiner's attention is directed to the references which are listed on the attached Forms PTO/SB/08A and PTO/SB/08B. Copies of the non-U.S. patent references are attached. This Statement is being accompanied by payment of the \$180 fee required under 37 CFR §1.17(p). Please charge any shortage or overpayment of the required fee to Deposit Account No. 50-0842.

Citation of these references is respectfully requested.

No concession is made that these documents are prior art, and Applicant expressly reserves the right to antedate the documents as may be appropriate.

peotfully submitted,

Reg. No. 52,20

File No. 017968-9010 US00 Michael Best & Friedrich LLP One South Pinckney Street P. O. Box 1806 Madison, WI 53701-1806

608.257.3501

PTO/SB/08A (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
a collection of information unless it contains a valid OMB contains.

Substitute for form 1	449/PTO	Col	Complete if Known		
		Application Number	10/550,165		
INFORMA	ATION DISCLOSUR	Filing Date	July 21, 2006		
		i First Named Inventor	Paul B. Savage		
	ENT BY APPLICAN	Art Unit	1623		
(Use a	s many sheets as necessary)	Examiner Name	Ganapathy Krishnan		
Sheet 1	of 1	Attorney Docket Number	017968-9010 US00		

			U. S. PATEN	T DOCUMENTS	
Examiner Initials*	No.1		Document Number Publication Date MM-DD-YYYY Number-Kind Code ² (If known)		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		^{US-} 5,780,441	07/14/1998	Higa et al.	
_		^{US-} 5,849,716	12/15/1998	Akimoto et al.	
		US-			
		US-	· · ·		
		US-			
		US-			-
		US-			
	-	US-			
		US-			

Cite No. ¹	Foreign Patent Document	Publication			FOREIGN PATENT DOCUMENTS Examiner Cite Foreign Patent Document Publication Name of Patentee or Pages Columns Lines					
		Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	Г					
	Country Code ³ -Number ⁴ -Kind Code ⁵ (<i>if known</i>)	MM-DD-YYYY	Typhical of Side Booking in	Or Relevant Figures Appear	T					
					Е					
.,										
					L					
					Ļ					
					L					
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Country Code ³ -Number ⁴ -Kind Code ⁵ (<i>if known</i>)	Country Code ³ -Number ⁴ -Kind Code ⁵ (<i>if known</i>)	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)					

Examiner		Date	
Signature	! .	Considered	
o.g.lata.o	, ·	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for fo	orm 1449B/PTO			Complete if Known		
				Application Number	10/550,165	
INFOR	MATION	N DISCL	OSURE	Filing Date	July 21, 2006	
STATE	MENT B	Y APPL	ICANT	First Named Inventor	Paul B. Savage	
				Group Art Unit	1623	
(use as many sheets as necessary)				Examiner Name	Ganapathy Krishnan	
Sheet	1	of	3	Attorney Docket Number	017968-9010 US00	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS
Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
BENLAGHA, K. et al., "In Vivo Identification of Glycolipid Antigen-specific T Cells Using Fluorescent CD1d Tetramers," J. Exp. Med. (2000) 191:11:1895-1903
COREY et al., "A New Method for the Synthesis of Organic Nitro Compounds," J. Am. Chem. Soc. (1984) 106:3682-3683
DASCHER, C.C. et al., "CD1 Antigen Presentation and Infectious Disease," Contributions to Microbiology (2003) 10:164-182
DAVIS, N.J. et al., "Chemical Synthesis of Disaccharides Which are Partial Structures of the Glycosaminoglycan Heparan Sulfate," J. Chem. Soc. (1994) 1:359-368
HASHIMOTO, S. et al., "Glycosylation Using Glucopyranosyl Fluorides and Silicon-Based Catalysts, Solvent Dependency of the Stereoselection," Tetrahedron Letters (1984) 25:13:1379-1382
HAYASHI, M. et al., "Simple Synthesis of Glycosyl Fluorides," Chem. Letters (1984) 1747-1750
KAWANO, T. et al., "CD1d-Restricted and TCR-Mediated Activation of Vα14 NKT Cells by Glycosylceramides," Science (1997) 278:1626-1629
KHAN, M. et al., "Syntheses and Antiinflammatory Activity of Some 6-aryl-2,3,4,5-tetrahydro-3-pyridazinones," Indian J. Chem. (2000) 39B:614-619
MIYAMOTO, K. et al., "A Synthetic Glycolipid Prevents Autoimmune Encephalomyelitis by Inducing T _H 2 Bias of Natural Killer T Cells," Nature (2001) 413:531-534

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for fo	orm 1449B/PTO				Complete if Known	
				Application Number	10/550,165	
INFOR	MATION	DISCL	OSURE	Filing Date	July 21, 2006	
STATE	STATEMENT BY APPLICANT			First Named Inventor	Paul B. Savage	
				Group Art Unit	1623	
(use as many sheets as necessary)				Examiner Name	Ganapathy Krishnan	
Sheet	2	of	3	Attorney Docket Number	017968-9010 US00	

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
	MORITA, M. et al., "Structure-Activity Relationship of α-Galactosylceramides Against B16-Bearing Mice," J. Med. Chem. (1995) 38:2176-2187
	NAKAGAWA, R. et al., "Mechanisms of the Antimetastatic Effect in the Liver and of the Hepatocyte Injury Induced by α-Galactosylceramide in Mice," J. Immun. (2001) 166:ll:6578-6584
	PAL, E. et al., "Costimulation-Dependent Modulation of Experimental Autoimmune Encephalomyelitis by Ligand Stimulation of Vα14 NK T Cells," J. Immunol. (2001) 166:662-668
	PARK, S.H. et al., "The Mouse CD1d-restricted Repetoire is Dominated by a Few Autoreactive T Cell Receptor Families," J. Exp. Med. (2001) 8:893-904
	PARK, S.H. et al., "CD1-Restricted T-Cell Responses and Microbial Infection," Nature (2000) 406:788-792
	SAKAI, T. et al., "Effects of α - and β -Galactosylated C2-Ceramides on the Immune System," J. Med. Chem. (1998) 41:650-652
	SINGH, P.P. et al., "The Synthesis of 2,3,4,6,7-Penta- <i>O</i> -Methyl-D- <i>glycero</i> -L- <i>manno</i> -Heptose and 2,4,6,7-Tetra- <i>O</i> -Methyl-D- <i>glycero</i> -L- <i>manno</i> -Heptose," Carbohydrate Res. (1970) 12:261-266
	TAKIKAWA et al., "Diastereoselective Epoxidation of the Double Bond at C-4 of Sphinogosines to Provide Phytosphingosine Relatives such as α-Galactosylceramide KRN7000," Tetrahedron (1998) 54:3141-3150
	VAULTIER, M. et al., Tetrahedron Letters (1983) 24:763 (NOT IN ENGLISH)
	I

Examiner	Date
Signature	Considered
	Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for fo	orm 1449B/PTO				Complete if Known	
				Application Number	10/550,165	
INFOR	MATION	N DISCL	OSURE	Filing Date	July 21, 2006	
STATE	STATEMENT BY APPLICANT			First Named Inventor	Paul B. Savage	
				Group Art Unit	1623	
	(use as many she	ets as necessary))	Examiner Name	Ganapathy Krishnan	1
Sheet	3	of	3	Attorney Docket Number	017968-9010 US00	

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
	WANG, B. et al., "CD1-Restricted NK T Cells Protect Nonobese Diabetic Mice from Developing Diabetes," J. Exp. Med. (2001) 194:313-319
	WANG, F. et al., "Tuning of Binding Selectivity: Metal Control of Organic Guest Binding and Allosteric Perturbation of Fluorescent Metal Sensor," J. Org. Chem. (1999) 64:8922-8928
	WEBER, G. et al., "Synthesis and Spectral Properties of a Hydrophobic Fluorescent Probe: 6-Propionyl-2-(dimethylamino) naphthalene," Biochem. (1979) 18:14:3075-3078

_	
Examiner	Date
Signature	
Signature	Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.